10-Q: Nephros Q2 Revenue Soars 36%, Returns to Profit

Nephros, Inc. reported a significant increase in net revenue and a return to net income for the second quarter and first half of 2025, driven by strong product sales and improved gross margins.

Summary

• Net revenue for the three months ended June 30, 2025, increased by 36% to $4.419 million, up from $3.252 million in the same period of 2024.
• Net revenue for the six months ended June 30, 2025, increased by 37% to $9.296 million, up from $6.774 million in the same period of 2024.
• The company achieved a net income of $237,000 for Q2 2025, a significant improvement from a net loss of $289,000 in Q2 2024.
• For the six months ended June 30, 2025, net income was $795,000, compared to a net loss of $458,000 in the prior year period.
• Gross margin improved to 63% in Q2 2025 (from 59% in Q2 2024) and 64% for H1 2025 (from 61% in H1 2024), primarily due to reduced shipping costs and inventory reserve adjustments.
• Operating income for Q2 2025 was $248,000, a substantial turnaround from an operating loss of $317,000 in Q2 2024.
• Net cash provided by operating activities was $1.316 million for the six months ended June 30, 2025, a significant improvement from net cash used of $1.173 million in the prior year period.
• Cash and cash equivalents increased to $5.074 million as of June 30, 2025, from $3.760 million at December 31, 2024.
• The accumulated deficit was reduced to $143.537 million as of June 30, 2025, from $144.332 million at December 31, 2024.
• A material weakness in internal control over financial reporting related to revenue recognition for contracts with multiple performance obligations was identified and is being remediated.

Sentiment

Score: 8

Explanation: The company demonstrated a strong financial turnaround with significant revenue growth, a return to profitability, and positive operating cash flow. While an accumulated deficit and an internal control weakness persist, the overall trend and management's strategic focus are highly positive.

Positives

• Strong revenue growth of 36% in Q2 2025 and 37% in H1 2025, driven by increased programmatic and emergency response sales.
• Return to profitability with net income of $237,000 in Q2 2025 and $795,000 in H1 2025, a significant turnaround from losses in the prior year.
• Improved gross margin percentages, reaching 63% in Q2 2025 and 64% in H1 2025, attributed to lower shipping costs and favorable product mix.
• Generated positive net cash from operating activities of $1.316 million in H1 2025, indicating improved operational efficiency and cash generation.
• Increased cash and cash equivalents balance to $5.074 million, strengthening the company's liquidity position.
• Reduced the accumulated deficit, reflecting progress towards sustained profitability.
• The company believes its current cash balances are sufficient to fund its operating plan for at least the next 12 months.

Negatives

• Selling, general and administrative expenses increased by 13% in Q2 2025 and 9% in H1 2025, primarily due to higher sales commissions, employee bonuses, and stock-based compensation.
• Research and development expenses increased by 22% in Q2 2025 and 30% in H1 2025, mainly due to higher salary expense and increased headcount.
• Incurred losses on foreign currency transactions, contributing to other expense of $32,000 in Q2 2025 and $53,000 in H1 2025.
• Concentration risk exists with two major customers (Customer A and B) accounting for 39% of Q2 2025 revenues and 34% of H1 2025 revenues, and 34% of accounts receivable as of June 30, 2025.
• An accumulated deficit of $143.5 million remains as of June 30, 2025, despite recent profitability.
• A material weakness in internal control over financial reporting related to revenue recognition was identified, though remediation efforts are underway.

Risks

• Significant challenges in obtaining market acceptance of products could adversely affect sales and revenues.
• Product-related deaths, serious injuries, or malfunctions could trigger recalls, class action lawsuits, and other events leading to expenses and negative publicity.
• Potential liability associated with product production, marketing, and sale, with defense costs potentially depleting assets and impairing reputation.
• Violation of U.S. Food, Drug and Cosmetic Act (FDC Act) or other regulations could lead to enforcement actions by the FDA or other governmental agencies.
• Inability to obtain funding when needed or on favorable terms to continue operations.
• Insufficient capital to successfully implement the business plan.
• Inability to effectively market products.
• Inability to sell water filtration products at competitive prices or profitably.
• Problems with suppliers, manufacturers, and distributors.
• Increased costs and/or disruptions in the supply chain due to U.S. tariffs.
• Unanticipated internal control deficiencies or weaknesses or ineffective disclosure controls and procedures.
• Inability to obtain appropriate or necessary regulatory approvals to achieve the business plan.
• Inability to secure or enforce adequate legal protection, including patent protection, for products.
• Inability to achieve sales growth in key geographic markets.
• Breach of the License and Supply Agreement with Medica S.p.A. if minimum annual purchase commitments for 2025 and beyond are not met.

Future Outlook

The company continues to focus on growth in sales and managing tight expenses to maintain profitability and positive cash flow from operations. Current cash balances are believed to be sufficient to fund the operating plan through at least the next 12 months. However, if operating results do not meet expectations, the company may need to further reduce discretionary expenditures such as headcount, R&D projects, and other variable costs. The company is also expanding its distribution in the commercial market to pursue other national accounts, which may lead to step-change increases in commercial market revenue over time.

Management Comments

• The increase in net revenue was primarily driven by increased revenue in both programmatic and emergency response, reflecting strong reorders and a number of new active sites.
• The improvement in gross profit margin was primarily driven by a reduction in shipping costs and inventory reserve adjustments, contributing to lower cost of goods sold.
• Operating plans are designed to help control operating costs and to increase revenue so we can continue to generate sufficient cash flows to fund operations.
• We believe that the same water safety management programs currently underway at medical facilities may migrate to commercial markets, and we expect building owners will come to understand ASHRAE-188 guidelines.
• We believe that we have an opportunity to offer unique expertise and products to the commercial market, and that our future revenue from the commercial market could even surpass our infection control revenue.

Industry Context

The company operates in the critical water filtration market, serving both medical (hospitals, dialysis centers for infection control) and commercial (hospitality, food service) sectors. The medical segment benefits from increasing regulatory requirements, such as CMS mandates for water management plans in healthcare facilities, driven by concerns over healthcare-associated infections (HAIs) from waterborne pathogens like Legionella and Pseudomonas. The company's FDA 510(k)-cleared medical devices provide a competitive advantage. In the commercial market, the company anticipates a growing demand for water safety management programs, similar to those in medical facilities, as awareness of waterborne pathogen epidemiology expands and corporate liability increases, aligning with standards like ASHRAE-188.

Corporate Governance

Stakeholder Impact

• Shareholders: Positive impact due to significant revenue growth, return to profitability, and positive operating cash flow, which could lead to increased shareholder value.
• Employees: Potential for higher sales commissions and employee bonuses due to increased revenue and profitability, but also a risk of headcount reduction if operating results do not meet expectations.
• Customers: Continued supply of high-performance water filtration products, with potential for expanded offerings in commercial markets.
• Suppliers: Continued business with key suppliers like Medica S.p.A. under extended agreements, subject to minimum purchase commitments.
• Creditors: Improved financial health and liquidity may enhance the company's creditworthiness.

Next Steps

• Continue to focus on growth in sales and managing tight expenses to maintain profitability and positive cash flow.
• Remediate the material weakness in internal control over financial reporting by establishing controls and protocols for proper revenue recognition from contracts with multiple performance obligations.
• Develop internal processes and controls, and provide additional training to the sales team, to properly capture relevant information for contract pricing.
• Expand distribution in the commercial market to pursue other national accounts, aiming for step-change increases in commercial market revenue.
• Assess the impact of the One Big Beautiful Bill Act (OBBBA) on consolidated financial statements, with an expectation of immaterial impact.

Key Dates

Recommendation

The filing indicates a strong financial turnaround for Nephros, Inc., with substantial revenue growth (36-37% year-over-year), a significant shift from net losses to net income, and positive operating cash flow. The improvement in gross margins further underscores operational efficiency. While an accumulated deficit and an identified internal control weakness exist, management is actively addressing these. The company's core business in medical and commercial water filtration is positioned to benefit from increasing regulatory demands and market awareness. The positive financial momentum and strategic focus on growth markets suggest a favorable outlook for investors.

Keywords

Water filtration, Medical devices, Infection control, Dialysis, Commercial water solutions, FDA 510(k), Ultrafilters, Healthcare facilities, Hospitality, Food service, SEC filing, Financial results, Quarterly report